Trial Profile
ASP 8825 Phase II Study-A Double- Blind, Placebo- Controlled Study in Patients With Painful Diabetic Polyneuropathy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2020
Price :
$35
*
At a glance
- Drugs Gabapentin enacarbil (Primary)
- Indications Neuropathic pain; Polyneuropathy
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 30 Nov 2008 Nov 2008 added as the actual completion date, based on information from ClinicalTrials.gov.
- 30 Nov 2008 Status changed from suspended to discontinued, based on information from ClinicalTrials.gov. An independent DMC concluded that continuation was unlikely to demonstrate a statistically significant advantage of ASP8825 over placebo for the primary endpoint.
- 12 Nov 2008 Status changed from recruiting to suspended, as reported by ClinicalTrials.gov. This trial has been suspended as an interim analysis is being conducted.